3D model (JSmol)
|Molar mass||196.25 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Fasoracetam appears to agonize all three metabotropic glutamate receptors and has improved cognitive function in rodent studies. It is orally available and is excreted mostly unchanged via the urine.
Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy.
Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson identified fasoracetam's potential use in attention deficit hyperactivity disorder. Hakonarson started a company called neuroFix Therapeutics, LLC to try to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts. neuroFix was acquired by Medgenics in 2015. Medgenics changed its name to Aevi Genomic Medicine in 2016. Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.
- FDA/NIH Substance registration system. Page accessed March 21, 2016
- "Drug Profile Fasoracetam".
- "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
- "Recommended INN List 40" (PDF). WHO Drug Information. 12 (2). 1998.
- Connolly, J; Glessner, J; Kao, C; Elia, J; Hakonarson, H. "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.". Ther Innov Regul Sci. 49(5): 632–642. PMC . PMID 26366330. doi:10.1177/2168479015599811.
- Malykh, AG; Sadaie, MR (12 February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.". Drugs. 70 (3): 287–312. PMID 20166767. doi:10.2165/11319230-000000000-00000.
- Moskowitz, D. H. (2017). Finding the Genetic Cause and Therapy for ADHD, Autism and 22q. BookBaby (self published). ISBN 9781483590981.
- Sharma, B. "Medgenics: NFC-1 Could Be A Key Future Revenue Driver.".
- "Press Release: Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc.". Aevi via MarketWired. 16 December 2016.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|